UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

The New England journal of medicine, 2017-08, Vol.377 (9), p.819-828

2017

Volltextzugriff (PDF)

Management of abdominal pseudotumours in haemophilia: a systematic review

Swiss medical weekly, 2023-08, Vol.153 (8), p.40094

2023

Volltextzugriff (PDF)

Correction: Colombatti et al. Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection. J. Clin. Med . 2023, 12 , 5538

Journal of clinical medicine, 2024-05, Vol.13 (10), p.2893

2024

Volltextzugriff (PDF)

Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection

Journal of clinical medicine, 2023-08, Vol.12 (17), p.5538

2023

Volltextzugriff (PDF)

Neonatal red blood cell transfusion practices in Switzerland: national survey and review of international recommendations

Swiss medical weekly, 2020-01, Vol.150, p.w20178

2020

Volltextzugriff (PDF)

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland

Swiss medical weekly, 2020-04

2020

Volltextzugriff (PDF)

Donor Age and Red Cell Age Contribute to the Variance in Lorrca Indices in Healthy Donors for Next Generation Ektacytometry: A Pilot Study

Frontiers in physiology, 2021-03, Vol.12, p.639722

2021

Volltextzugriff (PDF)

Role of Piezo1 in Terminal Density Reversal of Red Blood Cells

Cells (Basel, Switzerland), 2024-08, Vol.13 (16), p.1363

2024

Volltextzugriff (PDF)

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab: A consensus statement of the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network

Swiss medical weekly, 2020-12, Vol.150 (5153), p.w20422

2020

Volltextzugriff (PDF)

A pilot clinical phase II trial MemSID: Acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment

EJHaem, 2020-07, Vol.1 (1), p.23-34

2020

Volltextzugriff (PDF)

Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial

The Lancet (British edition), 2019-06, Vol.393 (10187), p.2201-2212

2019

Volltextzugriff (PDF)

Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis

Swiss medical weekly, 2020-04, Vol.150, p.w20247

2020

Volltextzugriff (PDF)

Correction: Colombatti et al. Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection. IJ. Clin. Med/I. 2023, I12/I, 5538

Journal of clinical medicine, 2024-05, Vol.13 (10)

2024

Volltextzugriff (PDF)

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

British journal of haematology, 2023-01, Vol.200 (2), p.229-239

2023

Volltextzugriff (PDF)

Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP

Current medical research and opinion, 2023-02, Vol.39 (2), p.219-225

2023

Volltextzugriff (PDF)

Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia

British journal of haematology, 2021-09, Vol.194 (5), p.931-934

2021

Volltextzugriff (PDF)

Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience

Acta haematologica, 2020-09, Vol.143 (5), p.504-508

2020

Volltextzugriff (PDF)

Use of nonacog beta pegol during surgery in persons with hemophilia B: a case series

Research and practice in thrombosis and haemostasis, 2023-10, Vol.7 (7), p.102208, Article 102208

2023

Volltextzugriff (PDF)

Daratumumab for immune thrombotic thrombocytopenic purpura

Blood advances, 2022-02, Vol.6 (3), p.993-997

2022

Volltextzugriff (PDF)

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

Blood, 2018-11, Vol.132 (Supplement 1), p.2477-2477

2018

Volltextzugriff (PDF)

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors

Blood, 2016-12, Vol.128 (22), p.1397-1397

2016

Volltextzugriff (PDF)

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

Blood, 2016-12, Vol.128 (22), p.2572-2572

2016

Volltextzugriff (PDF)

Treatment with Marstacimab for People with Severe Hemophilia a or B: a Plain Language Summary of the results from a short-term study and a longer-term study

Future Rare Diseases, 2023-12, Vol.3 (4)

2023

Volltextzugriff (PDF)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

Research and practice in thrombosis and haemostasis, 2019-04, Vol.3 (2), p.268-276

2019

Volltextzugriff (PDF)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Research and practice in thrombosis and haemostasis, 2019-07, Vol.3 (3), p.528-541

2019

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Management of abdominal pseudotumours in haemophilia: a systematic review

Correction: Colombatti et al. Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection. J. Clin. Med . 2023, 12 , 5538

Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection

Neonatal red blood cell transfusion practices in Switzerland: national survey and review of international recommendations

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland

Donor Age and Red Cell Age Contribute to the Variance in Lorrca Indices in Healthy Donors for Next Generation Ektacytometry: A Pilot Study

Role of Piezo1 in Terminal Density Reversal of Red Blood Cells

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab: A consensus statement of the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network

A pilot clinical phase II trial MemSID: Acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment

Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial

Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the Working Party Hemostasis

Correction: Colombatti et al. Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection. IJ. Clin. Med/I. 2023, I12/I, 5538

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP

Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia

Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience

Use of nonacog beta pegol during surgery in persons with hemophilia B: a case series

Daratumumab for immune thrombotic thrombocytopenic purpura

The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

Treatment with Marstacimab for People with Severe Hemophilia a or B: a Plain Language Summary of the results from a short-term study and a longer-term study

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

Suchergebnisse filtern